MedTrace Logo

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

NCT01306890 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1976

Last updated 2019-06-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Conditions

Interventions

BIOLOGICAL

sipuleucel-T

Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.

Sponsors & Collaborators

  • Dendreon

    lead INDUSTRY

Principal Investigators

  • Bruce Brown, MD · Dendreon Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-27
Primary Completion
2017-01-17
Completion
2017-01-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306890 on ClinicalTrials.gov